Drug Type Small molecule drug |
Synonyms Benserazide, PB 04, PB-04 + [2] |
Target |
Action inhibitors |
Mechanism DDC inhibitors(DOPA decarboxylase inhibitors), HK2 inhibitors(Hexokinase type II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H15N3O5 |
InChIKeyBNQDCRGUHNALGH-UHFFFAOYSA-N |
CAS Registry322-35-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Benserazide | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 1 | United States | 05 Nov 2021 | |
Beta-Thalassemia | Phase 1 | United States | 05 Nov 2021 | |
Non-Small Cell Lung Cancer | Preclinical | China | 01 Sep 2025 | |
Non-Small Cell Lung Cancer | Preclinical | Macao | 01 Sep 2025 |
Phase 1 | 10 | hkbbeklxjz(alpvwaoxjv) = uqniaaqjqz qxuzoinvai (xrctgffgsq ) View more | - | 09 Dec 2023 |